Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma

Yoshimatsu, Yuki; Noguchi, Rei; Sin, Yooksil; Tsuchiya, Ryuto; Ono, Takuya; Akiyama, Taro E.; Sato, Chiaki; Kobayashi, Eisuke; Kojima, Naoki; Yoshida, Akihiko; Kawai, Akira; Kondo, Tadashi

doi:10.1007/s13577-022-00749-7

Cited by 5 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The so-obtained results show that many of the analyzed drugs do not affect the proliferation of MFS cell lines. Furthermore, these cell lines have different sensitivities to tested drugs [62,63,65,66]. These studies confirm that MFS cells only respond to a limited number of drugs in vitro and are resistant to many others.…”

Section: Immortalized Mfs Cells Grown In Monolayer Culturessupporting

confidence: 63%

“…Despite being such an important feature of MFS, currently, we know very little about the migratory properties of MFS cell lines. Only a few papers have published results on the migration and invasion properties of MFS cells [13,55,59,63,65,66,72]. In some of them, the authors demonstrated that NCC-MFS-1-C1 and NCC-MFS2-C1 are able to invade the matrix using Matrigel invasion chambers [58,62]; moreover, Li et al showed that bortezomib inhibits the invasion potential of NMFH-1 cells [73].…”

Section: Immortalized Mfs Cells Grown In Monolayer Culturesmentioning

confidence: 99%

“…In some of them, the authors demonstrated that NCC-MFS-1-C1 and NCC-MFS2-C1 are able to invade the matrix using Matrigel invasion chambers [58,62]; moreover, Li et al showed that bortezomib inhibits the invasion potential of NMFH-1 cells [73]. It has also been demonstrated that the lines NCC-MFS4-C1 and NCC-MFS6-C1 are more invasive than the osteosarcoma MG63 cells [64,66]. In addition, Okada et al showed that the overexpression of integrin-A10 in MFS cells leads to an enhancement in cell migration and invasion in vitro [55].…”

Section: Immortalized Mfs Cells Grown In Monolayer Culturesmentioning

confidence: 99%

“…The most notable advantages of this model are its low production costs and high reproducibility. While some MFS cell lines form spheroids naturally, others need round-bottom and/or low attachment plates in order to do so [58,[62][63][64][65][66].…”

Section: Mfs Spheroids and Sarcospheresmentioning

confidence: 99%

See 3 more Smart Citations

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

Lucarelli,

De Vita,

Bellotti

et al. 2023

Cancers

View full text Add to dashboard Cite

Myxofibrosarcoma (MFS) is a malignant soft tissue sarcoma (STS) that originates in the body’s connective tissues. It is characterized by the presence of myxoid (gel-like) and fibrous components and typically affects patients after the fifth decade of life. Considering the ongoing trend of increasing lifespans across many nations, MFS is likely to become the most common musculoskeletal sarcoma in the future. Although MFS patients have a lower risk of developing distant metastases compared with other STS cases, MFS is characterized by a high frequency of local recurrence. Notably, in 40–60% of the patients where the tumor recurs, it does so multiple times. Consequently, patients may undergo multiple local surgeries, removing the risk of potential amputation. Furthermore, because the tumor relapses generally have a higher grade, they exhibit a decreased response to radio and chemotherapy and an increased tendency to form metastases. Thus, a better understanding of MFS is required, and improved therapeutic options must be developed. Historically, preclinical models for other types of tumors have been instrumental in obtaining a better understanding of tumor development and in testing new therapeutic approaches. However, few MFS models are currently available. In this review, we will describe the MFS models available and will provide insights into the advantages and constraints of each model.

show abstract

Section: Immortalized Mfs Cells Grown In Monolayer Culturessupporting

confidence: 63%

Section: Immortalized Mfs Cells Grown In Monolayer Culturesmentioning

confidence: 99%

Section: Immortalized Mfs Cells Grown In Monolayer Culturesmentioning

confidence: 99%

Section: Mfs Spheroids and Sarcospheresmentioning

confidence: 99%

See 2 more Smart Citations

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

Lucarelli,

De Vita,

Bellotti

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…We meticulously characterized the NCC-MFS7-C1 and NCC-MFS8-C1 cell lines and examined their genetic pro les, proliferation rates, spheroid formation capabilities, and invasive behaviors. Additionally, we expanded our investigation to include drug screening across these novel cell lines and six others previously established in our laboratory with the aim of identifying potential therapeutic indications for MFS [15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Establishment and characterization of two novel patient-derived cell lines from myxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1

Adachi,

Noguchi,

Osaki

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Myxofibrosarcoma (MFS), an aggressive soft tissue sarcoma, presents a significant challenge because of its high recurrence rate, distal metastasis, and complex genetic background. Although surgical resection is the standard treatment for MFS, the outcomes are unsatisfactory, and effective non-surgical treatment strategies, including drug therapy, are urgently warranted. MFS is a rare tumor that requires comprehensive preclinical research to develop promising drug therapies; however, only two MFS cell lines are publicly available worldwide. The present study reports two novel patient-derived MFS cell lines, NCC-MFS7-C1 and NCC-MFS8-C1. These cell lines have been extensively characterized for their genetic profile, proliferation, spheroid-forming capacity, and invasive behavior, confirming that they retain MFS hallmarks. Furthermore, we conducted comprehensive drug screening against these cell lines and six others previously established in our laboratory to identify potential therapeutic candidates for MFS. Among the screened agents, actinomycin D, bortezomib, and romidepsin demonstrated considerable antiproliferative effects that were superior to those of doxorubicin, a standard drug, highlighting their potential as novel drugs. In conclusion, NCC-MFS7-C1 and NCC-MFS8-C1 are valuable research resources that contribute to the understanding of the pathogenesis and development of novel therapies for MFS.

show abstract